Nitrosamine Impurities Affecting Drug-Drug Interaction Studies – Learn More

NASH Summit

Visit the Site

There has been a rise and fall of investment in NASH in the wake of highly demanding biopsy endpoints and late-stage clinical setbacks. However, a surge of interest in approaching metabolic syndrome more holistically, pivotal readouts in GLP-1 receptor agonists for the treatment of obesity, and trailblazing approaches to innovative trial design have resurrected and transformed the landscape for drug development in obesity, NASH, and other metabolic disorders.

Uniting industry experts dedicated to accelerating the frontier of therapeutic development in metabolic syndrome, the 6th Obesity & NASH Drug Development Summit (previously the NASH Summit), is the definitive industry forum sharing cross-industry insight to drive holistic approaches to drug development in metabolic syndrome.

Join 150+ industry experts from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Pfizer, Inventiva, Regeneron, Bayer, Gilead, FDA, AstraZeneca, and many more confirmed to attend. With sessions from delineating the latest advances in exciting targets including GLP-1 receptor agonists and progress in regenerative medicine, to reimagining inclusion criteria in clinical trials, this is your opportunity to de-risk the pathway to life-changing therapeutics for obesity, NASH and type 2 diabetes.

As we are at the precipice of unprecedented validation of non-invasive biomarkers, breakthroughs in exciting targets, and a reimagined approach to patient inclusion in trials with precision medicine, this is a conversation you won’t want to miss.